세계의 방사성 의약품 시장 : 유형별, 수기량별, 용도별 예측(2025-2030년)

The Radiopharmaceuticals Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.48 billion in 2024, and is projected to grow at a CAGR of 6.47%, to USD 8.00 billion by 2030.

Radiopharmaceuticals are radioactive compounds used for diagnosis, treatment, and research within the medical field. They play a pivotal role in nuclear medicine, primarily used in imaging and therapeutic applications. The necessity of radiopharmaceuticals stems from their ability to target specific organs, tissues, or cellular receptors, thereby enabling precise diagnostic imaging and effective treatment of diseases like cancer, cardiovascular ailments, and neurological disorders. End-use applications primarily involve hospitals, diagnostic centers, and specialized clinics. Key influencing growth factors include an increasing prevalence of chronic diseases, advancements in imaging technologies, and a growing geriatric population, which drives the demand for precise diagnostic tools and personalized treatment strategies. The rapid advancements in radiopharmaceuticals for targeted therapy, along with rising investment in research and development, present significant opportunities. Companies could capitalize on these by focusing on niche indications or developing cost-effective and efficient production methods.

One limitation is the high cost related to the production and regulatory compliance inherent in handling radioactive materials, which poses a barrier to entry and innovation. Additionally, the need for sophisticated infrastructure and skilled personnel adds to market constraints. Intellectual property hurdles and a lengthy approval process further complicate rapid market penetration.

For business growth, research into new isotopes with better efficacy and lower side effects is promising. Innovation in imaging techniques and developing new clinical applications can pave the way for expansion. There is also potential in exploring collaborations between biotechnology firms and healthcare providers to integrate radiopharmaceuticals into existing treatment frameworks more effectively.

The nature of the market is highly regulated and competitive, with significant investments in R&D necessary for maintaining a competitive edge. As healthcare policies evolve and technology advances, adapting swiftly to these changes by focusing on emerging markets and untapped applications can provide strategic advantages.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Radiopharmaceuticals Market

The Radiopharmaceuticals Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing Incidence and Prevalence of Target Conditions
  • Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
  • Initiatives To Reduce The Demand-Supply Gap of mo-99
• Market Restraints
  • Shorter Life of Radiopharmaceuticals
• Market Opportunities
  • Adoption of Radiopharmaceuticals in Neurological Applications
  • Rising Number of Diagnostic Centers Especially in Developing Countries
• Market Challenges
  • High Equipment Prices and Limited Hospital Budget

Porter's Five Forces: A Strategic Tool for Navigating the Radiopharmaceuticals Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Radiopharmaceuticals Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Radiopharmaceuticals Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Radiopharmaceuticals Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Radiopharmaceuticals Market

A detailed market share analysis in the Radiopharmaceuticals Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Radiopharmaceuticals Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Radiopharmaceuticals Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Radiopharmaceuticals Market, highlighting leading vendors and their innovative profiles. These include Global Medical Solutions, Siemens Healthineers AG, Fusion Pharmaceuticals Inc., Novartis AG, International Isotopes, Inc., Northstar Medical Technologies LLC, Institute of Isotopes Co. Ltd., Jubilant Pharma Holdings Inc., IsoTherapeutics Group, LLC, Eckert & Ziegler Group, Isotopia Molecular Imaging Ltd., GE HealthCare Technologies, Inc., BWX Technologies. Inc., Clarity Pharmaceuticals, Eczacibasi-Monrol Nuclear Products Co., Alliance Holdings Medical Limited, Cardinal Health, Inc., Mallinckrodt PLC, Bracco Group, NTP Radioisotopes SOC Ltd., Curium Pharma, Medi-Radiopharma, Sinotau Pharmaceutical Group, State Atomic Energy Corporation Rosatom, SHINE Medical Technologies, Lantheus Medical Imaging, Inc., Bayer AG, and BWXT Medical Ltd..

Market Segmentation & Coverage

This research report categorizes the Radiopharmaceuticals Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Diagnostic Nuclear Medicine and Therapeutic Nuclear Medicine. The Diagnostic Nuclear Medicine is further studied across Pet Radiopharmaceuticals and Spect Radiopharmaceuticals. The Pet Radiopharmaceuticals is further studied across F-18 and Ru-82. The Spect Radiopharmaceuticals is further studied across Ga-67, I-123, Tc-99m, and Tl-201. The Therapeutic Nuclear Medicine is further studied across Alpha Emitters, Beta Emitters, and Brachytherapy Isotopes. The Beta Emitters is further studied across I-131, Lu-177, Re-186, Sm-153, and Y-90. The Brachytherapy Isotopes is further studied across Cs-131, I-125, Ir-192, and Pd-103.
• Based on Procedural Volume, market is studied across Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures is further studied across Pet Radiopharmaceutical Procedure and Spect Radiopharmaceuticals Procedure. The Therapeutic Procedures is further studied across Alpha Emitter Procedure, Beta Emitters Procedure, and Brachytherapy Isotopes Procedure.
• Based on Application, market is studied across Diagnostic Applications and Therapeutic Applications. The Diagnostic Applications is further studied across Pet Applications and Spect Applications. The Pet Applications is further studied across Cardiology Indication, Neurology Indication, and Oncology Indication. The Spect Applications is further studied across Cardiology, Lymphoma, Neurology, and Thyroid. The Therapeutic Applications is further studied across Bone Metastasis, Endocrine Tumors, Lymphoma Therapeutic, and Thyroid Therapeutic.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing Incidence and Prevalence of Target Conditions
    • 5.1.1.2. Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
    • 5.1.1.3. Initiatives To Reduce The Demand-Supply Gap of mo-99
  • 5.1.2. Restraints
    • 5.1.2.1. Shorter Life of Radiopharmaceuticals
  • 5.1.3. Opportunities
    • 5.1.3.1. Adoption of Radiopharmaceuticals in Neurological Applications
    • 5.1.3.2. Rising Number of Diagnostic Centers Especially in Developing Countries
  • 5.1.4. Challenges
    • 5.1.4.1. High Equipment Prices and Limited Hospital Budget
• 5.2. Market Segmentation Analysis
  • 5.2.1. Procedural Volume: Ongoing advancements in brachytherapy isotopes procedure
  • 5.2.2. Application: Increasing utilization of radiopharmaceuticals in therapeutic procedures
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Radiopharmaceuticals Market, by Type

• 6.1. Introduction
• 6.2. Diagnostic Nuclear Medicine
  • 6.2.1. Pet Radiopharmaceuticals
    • 6.2.1.1. F-18
    • 6.2.1.2. Ru-82
  • 6.2.2. Spect Radiopharmaceuticals
    • 6.2.2.1. Ga-67
    • 6.2.2.2. I-123
    • 6.2.2.3. Tc-99m
    • 6.2.2.4. Tl-201
• 6.3. Therapeutic Nuclear Medicine
  • 6.3.1. Alpha Emitters
  • 6.3.2. Beta Emitters
    • 6.3.2.1. I-131
    • 6.3.2.2. Lu-177
    • 6.3.2.3. Re-186
    • 6.3.2.4. Sm-153
    • 6.3.2.5. Y-90
  • 6.3.3. Brachytherapy Isotopes
    • 6.3.3.1. Cs-131
    • 6.3.3.2. I-125
    • 6.3.3.3. Ir-192
    • 6.3.3.4. Pd-103

7. Radiopharmaceuticals Market, by Procedural Volume

• 7.1. Introduction
• 7.2. Diagnostic Procedures
  • 7.2.1. Pet Radiopharmaceutical Procedure
  • 7.2.2. Spect Radiopharmaceuticals Procedure
• 7.3. Therapeutic Procedures
  • 7.3.1. Alpha Emitter Procedure
  • 7.3.2. Beta Emitters Procedure
  • 7.3.3. Brachytherapy Isotopes Procedure

8. Radiopharmaceuticals Market, by Application

• 8.1. Introduction
• 8.2. Diagnostic Applications
  • 8.2.1. Pet Applications
    • 8.2.1.1. Cardiology Indication
    • 8.2.1.2. Neurology Indication
    • 8.2.1.3. Oncology Indication
  • 8.2.2. Spect Applications
    • 8.2.2.1. Cardiology
    • 8.2.2.2. Lymphoma
    • 8.2.2.3. Neurology
    • 8.2.2.4. Thyroid
• 8.3. Therapeutic Applications
  • 8.3.1. Bone Metastasis
  • 8.3.2. Endocrine Tumors
  • 8.3.3. Lymphoma Therapeutic
  • 8.3.4. Thyroid Therapeutic

9. Americas Radiopharmaceuticals Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Radiopharmaceuticals Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Radiopharmaceuticals Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
  • 12.3.2. New CRP to Develop new Technetium-99m Radiopharmaceuticals for Disease Diagnosis
  • 12.3.3. With USD 56 Million, a Mayo Clinic-backed Startup takes aim at Radiopharmaceutical Roadblocks

Companies Mentioned

• 1. Global Medical Solutions
• 2. Siemens Healthineers AG
• 3. Fusion Pharmaceuticals Inc.
• 4. Novartis AG
• 5. International Isotopes, Inc.
• 6. Northstar Medical Technologies LLC
• 7. Institute of Isotopes Co. Ltd.
• 8. Jubilant Pharma Holdings Inc.
• 9. IsoTherapeutics Group, LLC
• 10. Eckert & Ziegler Group
• 11. Isotopia Molecular Imaging Ltd.
• 12. GE HealthCare Technologies, Inc.
• 13. BWX Technologies. Inc.
• 14. Clarity Pharmaceuticals
• 15. Eczacibasi-Monrol Nuclear Products Co.
• 16. Alliance Holdings Medical Limited
• 17. Cardinal Health, Inc.
• 18. Mallinckrodt PLC
• 19. Bracco Group
• 20. NTP Radioisotopes SOC Ltd.
• 21. Curium Pharma
• 22. Medi-Radiopharma
• 23. Sinotau Pharmaceutical Group
• 24. State Atomic Energy Corporation Rosatom
• 25. SHINE Medical Technologies
• 26. Lantheus Medical Imaging, Inc.
• 27. Bayer AG
• 28. BWXT Medical Ltd.